Patents Examined by Alana M. Harris
-
Patent number: 7939073Abstract: B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 or CD19 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 and/or anti-CD19 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.Type: GrantFiled: October 21, 2005Date of Patent: May 10, 2011Assignee: Immunomedics, Inc.Inventor: David M. Goldenberg
-
Patent number: 7939321Abstract: The present invention provides DNA encoding a TADG-15 protein as well as a TADG-15 protein. Also provided is a vector capable of expressing the DNA of the present invention adapted for expression in a recombinant cell and regulatory elements necessary for expression of the DNA in the cell. The present invention further provides for methods of inhibiting TADG-15 expression and/or protease activity, methods of detecting TADG-15 mRNA and/or protein and methods of screening for TADG-15 inhibitors. Additionally, the present invention provides for cell-specific targeting via TADG-15 and methods of vaccinating an individual against TADG-15. The methods described are useful in the diagnosis, treatment and prevention of cancer, particularly breast and ovarian cancer.Type: GrantFiled: October 29, 2007Date of Patent: May 10, 2011Assignee: Board of Trustees of the University of ArkansasInventors: Timothy J. O'Brien, Hirotoshi Tanimoto
-
Patent number: 7939274Abstract: The invention relates to novel nucleic acids encoding a mammalian PCADM-1 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, prostate cancer. The invention further relates to methods of detecting and treating prostate cancer, comprising modulating or detecting PCADM-1 expression and/or production and activity of PCADM-1 polypeptide. Further, the invention relates to novel assays for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them. Finally, the invention relates to DNAZYMs or DNA enzymes which specifically bind PCADM-1 mRNA to inhibit PCADM-1 gene expression and thereby destroy tumor cells and tumor tissue.Type: GrantFiled: May 18, 2010Date of Patent: May 10, 2011Assignee: Philadelphia Health and Education CorporationInventors: Mark Stearns, Youji Hu, Min Wang
-
Patent number: 7939080Abstract: There is disclosed a pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of (a) an isolated polypeptide having from about 50 to 79 amino acids taken from the sequence of SEQ ID NO:1, wherein the polypeptide binds to the extracellular domain ECD of HER-2 at an affinity of at least 108, (b) an isolated and glycosylated polypeptide having from about 300 to 419 amino acids taken from the sequence of SEQ ID NO:2, wherein the C terminal 79 amino acids are present, and wherein at least three N-linked glycosylation sites are present, (c) a monoclonal antibody that binds to the ECD of HER-2, and (d) combinations thereof, with the proviso that the agent cannot be the monoclonal antibody alone, and pharmaceutically acceptable carrier.Type: GrantFiled: June 30, 2008Date of Patent: May 10, 2011Assignee: Oregon Health & Science UniversityInventors: Joni K. Doherty, Gail M. Clinton, John P. Adelman
-
Patent number: 7935350Abstract: Provided are methods and compositions for treating cancer in humans, the cancer being characterized by expression of Her-2/neu. The methods involve vaccinating a patient with an Ii-Key/MHC class II hybrid construct and thereby stimulating an immune response to the native Her-2/neu protein. The construct may be in the form of an Ii-Key hybrid peptide or a nucleic acid encoding an Ii-Key hybrid peptide. Methods are described wherein the cancer being treated is breast cancer. Also claimed is a pharmaceutical composition comprising an Ii-Key/MHC class II hybrid construct with and without an adjuvant. The adjuvant can include GM-CSF. The Ii-Key hybrid construct includes the LRMK (SEQ ID NO: 2) residues of Ii-Key protein and an MHC Class II epitope of a protein or portion thereof which is used in the vaccine or a DNA encoding the same hybrid peptide.Type: GrantFiled: December 13, 2007Date of Patent: May 3, 2011Assignee: Antigen Express, Inc.Inventors: Robert E. Humphreys, Minzhen Xu
-
Patent number: 7932360Abstract: The invention provides methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.Type: GrantFiled: November 6, 2006Date of Patent: April 26, 2011Assignee: Merus B.V.Inventors: Patrick H. C. Van Berkel, Ronald Hendrik Peter Brus, Ton Logtenberg, Abraham Bout
-
Patent number: 7932047Abstract: The present invention relates to a method for the early diagnosis of neoplastic disorders such as cancers as well as their precursor stages, particularly cancers of the respiratory tract, the urinary system, the reproductive tract, cancer associated with HPV infection or cancer of the anogenital tract, from solubilized body samples. The invention is also directed to test kits usable for this purpose as well as in-vitro diagnostic devices. The development of the kits and in-vitro diagnostic devices for the above purpose is also one aspect of the present invention.Type: GrantFiled: August 20, 2004Date of Patent: April 26, 2011Assignee: MTM Laboratories, AGInventors: Ruediger Ridder, Anja Reichert, Magnus Von Knebel Doeberitz, Matthias Herkert, Alexander Duwe, Rainer Hipfel, Peter Martin
-
Patent number: 7927814Abstract: Disclosed is a novel method for determination of ProGRP which is free from problems such as the dispersion in the values of measurements and operational constraints such as handling of a test sample. A method for the determination of a gastrin-releasing peptide precursor or a digest thereof using at least two different antibodies each of which can recognize a peptide comprising the partial amino acid sequence starting from amino acid residue 40 and ended at amino acid residue 75 in the amino acid sequence depicted in SEQ ID NO:1; and a method for the determination of a gastrin-releasing peptide precursor and/or a digest thereof using at least two different antibodies each of which can recognize a peptide comprising the partial amino acid sequence starting from amino acid residue 40 and ended at amino acid residue 79 in the amino acid sequence depicted in SEQ ID NO:1.Type: GrantFiled: October 15, 2007Date of Patent: April 19, 2011Assignee: Advanced Life Science Institute, Inc.Inventor: Katsumi Aoyagi
-
Patent number: 7910551Abstract: The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to methods of treating or preventing a disorder in a subject. The invention further relates to uses of C35 polypeptides in immunogenic compositions or vaccines, to induce antibody or T cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene. The present invention further relates to use of C35 polypeptides in diagnosing a pathological condition or susceptibility to a pathological condition in a subject.Type: GrantFiled: February 26, 2009Date of Patent: March 22, 2011Assignee: University of RochesterInventors: Maurice Zauderer, Elizabeth E. Evans, Melinda A. Borrello
-
Patent number: 7910103Abstract: B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 or CD19 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 and/or anti-CD19 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.Type: GrantFiled: October 1, 2001Date of Patent: March 22, 2011Assignee: Immunomedics, Inc.Inventor: David M. Goldenberg
-
Patent number: 7910704Abstract: Novel human p53 splice variant displaying differential transcriptional activity Described is a nucleic acid molecule encoding a p53 variant characterized in that it is capable of transactivating the p21- and 14-3-3?-promoter but not the mdm2-, bax- and PIG3-promoter. Preferably, in said p53 variant exon 7, exon 8 and/or exon 9 are partially or entirely deleted. Finally, means for inhibiting the activity of this p53 variant are described which are useful for the therapy of cancer.Type: GrantFiled: September 27, 2005Date of Patent: March 22, 2011Inventors: Wolfgang W. Deppert, Irene Dornreiter
-
Patent number: 7906294Abstract: The present invention relates to an antibody which specifically binds a Spot 14 (S14 or THRSP) protein in human breast cancer cells and a method for using the same to predict disease-free survival and select treatment modalities for breast cancer. The present invention is also a method for inducing apoptosis in breast cancer cells by inhibiting the expression or activity of Spot 14. Compositions and methods for treating breast cancer are also provided.Type: GrantFiled: May 12, 2006Date of Patent: March 15, 2011Assignee: Trustees of Dartmouth CollegeInventor: William B. Kinlaw, III
-
Patent number: 7892542Abstract: This invention relates to human anti-idiotypic antibody fragments, especially scFv, characterized by the ability to mimic Her-2/neu tumor associated antigen. These antibody fragments are promising candidates for active immunotherapy for cancer patients positive for Her-2/neu.Type: GrantFiled: December 14, 2004Date of Patent: February 22, 2011Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre Regional de Lutte Contre le Cancer “Val d'Aurelle-Paul Lamarque”, Universite Montpellier IInventors: Philippe Gauthier, André Pelegrin, Mickaël Coelho, Isabelle Teulon
-
Patent number: 7893204Abstract: The present disclosure provides attractin/mahogany-like polypeptides and fragments thereof, polynucleotides encoding such polypeptides and fragments, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides or fragments, and assays and methods employing these polypeptides, antibodies, and polynucleotides.Type: GrantFiled: April 22, 2008Date of Patent: February 22, 2011Assignee: Immunex CorporationInventor: Dirk M. Anderson
-
Patent number: 7892549Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin.Type: GrantFiled: February 3, 2003Date of Patent: February 22, 2011Assignee: Genentech, Inc.Inventors: Virginia E. Paton, Steven Shak, Susan D. Hellmann
-
Patent number: 7892730Abstract: The present invention relates to novel sequences for use in diagnosis and treatment of carcinomas, especially lymphoma carcinomas. In addition, the present invention describes the use of novel compositions for use in screening methods.Type: GrantFiled: March 1, 2002Date of Patent: February 22, 2011Assignee: Sagres Discovery, Inc.Inventors: David W. Morris, Eric K. Engelhard
-
Patent number: 7892554Abstract: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.Type: GrantFiled: June 1, 2007Date of Patent: February 22, 2011Assignee: The Regents of the University of CaliforniaInventors: James D. Marks, Marie Alix Poul
-
Patent number: 7887808Abstract: Naturally-occurring variants of human Rgr oncogene protein, in particular, abnormally truncated variants found in T cell malignancies, as well as the human Rgr protein are encompassed by the present invention. Also included are antibodies thereto and nucleic acid molecules encoding human Rgr protein and naturally-occurring variants thereof. The present invention further provides methods for diagnosing and treating T cell malignancies associated with abnormally truncated transcripts of human rgr oncogene and/or abnormal truncation of human Rgr protein.Type: GrantFiled: April 25, 2008Date of Patent: February 15, 2011Assignee: New York UniversityInventors: Angel Pellicer, Peter Leonardi, Giorgio Inghirami
-
Patent number: 7883702Abstract: The present invention relates to cancer therapies using an antibody that binds to mortalin 2 and a functional nucleic acid. Mortalin expression was found to be upregulated in immortalized cells and tumor tissues. Immortalized human cells highly expressing mortalin showed anchorage-independent growth. When the K antibody, which is a specific anti-mortalin antibody, was injected into a tumor of a nude mouse, tumor growth was suppressed or the tumor shrank compared with the case of a control. In accordance with the present invention, the use of a specific anti-mortalin antibody (K antibody) for tumor therapies and the use of such antibody as a carrier molecule for transportation of immunotoxicin and the like into cells are provided. It has been shown that mortalin can be a target for cancer therapies. In accordance with the present invention, a novel and effective anticancer agent is provided. In addition, an anti-mortalin antibody that is internalized by cells is developed.Type: GrantFiled: August 25, 2005Date of Patent: February 8, 2011Assignee: National Institute of Advanced Industrial Science and TechnologyInventors: Renu Wadhwa, Kazunari Taira, Sunil Kaul
-
Patent number: 7879327Abstract: A medicament for treating cancer for use in combination therapy with an anti-HER2 antibody, which comprises amrubicin or a pharmaceutically acceptable salt thereof as an active ingredient.Type: GrantFiled: June 11, 2007Date of Patent: February 1, 2011Assignee: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Toshihiro Noguchi, Akemi Baba, Mitsuharu Hanada